Serverless computing in omics data analysis and integration.

A comprehensive analysis of omics data can require vast computational resources and access to varied data sources that must be integrated into complex, multi-step analysis pipelines. Execution of many such analyses can be accelerated by applying the cloud computing paradigm, which provides scalable resources for storing data of different types and parallelizing data analysis computations. Moreover, these resources can be reused for different multi-omics analysis scenarios.

One-Time Optimization of Advanced T Cell Culture Media Using a Machine Learning Pipeline.

The growing application of cell and gene therapies in humans leads to a need for cell type-optimized culture media. Design of Experiments (DoE) is a successful and well known tool for the development and optimization of cell culture media for bioprocessing. When optimizing culture media for primary cells used in cell and gene therapy, traditional DoE approaches that depend on interpretable models will not always provide reliable predictions due to high donor variability.

A Large-Scale and Serverless Computational Approach for Improving Quality of NGS Data Supporting Big Multi-Omics Data Analyses.

Various types of analyses performed over multi-omics data are driven today by next-generation sequencing (NGS) techniques that produce large volumes of DNA/RNA sequences. Although many tools allow for parallel processing of NGS data in a Big Data distributed environment, they do not facilitate the improvement of the quality of NGS data for a large scale in a simple declarative manner. Meanwhile, large sequencing projects and routine DNA/RNA sequencing associated with molecular profiling of diseases for personalized treatment require both good quality data and appropriate infrastructure for efficient storing and processing of the data.

ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity.

ONCR-177 is an engineered recombinant oncolytic herpes simplex virus (HSV) with complementary safety mechanisms, including tissue-specific miRNA attenuation and mutant UL37 to inhibit replication, neuropathic activity, and latency in normal cells. ONCR-177 is armed with five transgenes for IL12, FLT3LG (extracellular domain), CCL4, and antagonists to immune checkpoints PD-1 and CTLA-4. assays demonstrated that targeted miRNAs could efficiently suppress ONCR-177 replication and transgene expression, as could the HSV-1 standard-of-care therapy acyclovir.